$ASTS is taking a massive hit following SpaceX's $8B spectrum deal and FCC approval for 15,000 direct-to-phone satellites. But we always kind of knew SpaceX was going to expand Starlink into mobile connectivity. This was always going to be a competitive market. The question now is whether the satellite-to-phone market is large enough for multiple companies to succeed. Can both ASTS and SpaceX become major winners in this space?

$IREN, $NBIS, $CRWV Elon Musk is right. People have no idea what's coming. We've been investing in the AI data centre sector since 2024, and the crazy part is that two years later, we're still only getting started. I genuinely believe retail investors who recognised this opportunity early are sitting on one of the biggest investment trends of the next decade. Think about what's coming. Millions of AI agents working around the clock, businesses automating entire workflows, and AI becoming part of almost everything we do. All of that requires enormous amounts of computing power, electricity, memory and data centre infrastructure. The demand we're seeing today could be tiny compared to what's coming over the next five to ten years. We've already witnessed an extraordinary two years in this sector, yet the next phase could be significantly bigger.

$HIMS - We have subscriptions for almost everything now, but very few become memberships people keep for years. Costco and Amazon Prime are two of the best examples. They started with a simple reason to join, then kept adding more value around the membership. Over time, customers had more reasons to stay, use more services and renew every year. Costco's US and Canada renewal rate is now above 92%. I think this is what Hims is building toward in healthcare. Today, someone might join Hims for one specific reason, such as hair loss or weight loss. That also means they can leave once they no longer need that treatment. The way Hims improves retention is by giving that same person more reasons to stay. As Hims expands into testing, it can understand far more about each person's health and use that information to recommend what they should focus on next. From there, Hims can offer the treatments, ongoing care and monitoring needed to manage their health over time. In simple terms, as Hims adds more services, existing subscribers have more reasons to stay, former subscribers have more reasons to return, and every new subscriber becomes more valuable over time. Customer acquisition got Hims to millions of subscribers. Building a membership people don't want to leave should take it much further.

The S&P 500 just hit another all-time high. If you want a simpler, less stressful investing life, there's absolutely nothing wrong with investing in the S&P 500. Start early. Invest regularly. Stay invested. You don't need to beat the market to build serious wealth.

There's a clear pattern in the moves $HIMS has made lately, and it shows where Andrew Dudum is taking the company. Hims is becoming the platform people use to manage their health throughout their whole lives. First came the GRAIL partnership, which put Galleri cancer screening on the platform at $250 off the $949 list price for Labs members. One blood draw looks for a signal from more than 50 types of cancer. Now Hims has invested in Arboretum, a genetic testing company that launched this week with a $30M Series A, with Hims in the round alongside GV and Amgen. Arboretum's tests look at inherited disease risk. The results show doctors who needs earlier screening, closer monitoring or a particular treatment. Finding the inherited condition behind very high cholesterol, for example, means treatment can start earlier and the risk of heart disease comes down. That is how genetic testing turns into more personalised care. Hims already has the base for this. Labs launched in November 2025 with blood testing through Quest Diagnostics, and Dudum has said he sees it eventually becoming a $1B business. Hims will keep adding to that: genetic results, blood tests, medical history and ongoing treatment in one place, with a care plan that changes as the customer's health changes. Very bullish for long-term.

$ONDS spent the past year acquiring companies nonstop. Now I expect those acquisitions to start securing deals nonstop. Recent orders: • Jun 22 - $40M+ Autonomous Defense • Jul 20 - $6.9M Australian Defence • Jul 22 - $70M Autonomous Defense • Aug 5 - $50M+ U.S. Army • Oct 5 - $56M Precision Strike Over $220M in announced orders.

Commit this October to: • Sleep by 11pm • No alcohol/sugar • Track what you eat • 10k steps every day • 4 workouts per week • Drink 3L of water daily • Meal prep every Sunday • Morning walk before screens • Weigh yourself every Monday

Some investors will make their first million early. Some will take decades. Some will find a 10x on their first few investments. Others will make countless mistakes before finding their biggest winners. But remember, there is no deadline in investing. Focus on your own journey.

There will always be a reason not to invest. Yet $10,000 invested in global equities at the end of 1994 would have grown to roughly $56,900 by the end of 2024, or $80,800 with dividends reinvested. Time in the market beats trying to wait for a world with nothing to worry about.

$IREN generated $70.5M in AI Cloud revenue last quarter. By August, ARR had already reached $1B and is set to surpass $4B by year-end. That puts IREN on track to go from $70M in quarterly AI revenue to a $1B quarterly run rate. The growth is about to explode.

Six months ago I started this investing account following Peter Wolff's strategy with most of my money. I want to be honest about why: I didn't trust myself yet. Following someone better than me, while I learned, beat pretending I already knew what I was doing. That wasn't a placeholder. It was the right call, and it taught me the thing I needed most. Wolff taught me discipline. Not reacting to every green or red candle. Sitting still when sitting still is the hardest thing to do. Letting a thesis play out instead of flinching every time the market had an opinion. He's also where I learned to dollar-cost average with a steady hand, and how to actually research a company instead of buying a story. Conviction I learned from @moninvestor , someone on here whose thinking sharpened mine more than he knows. How to believe in something enough to hold it when it's down 30% and the headlines say you're an idiot. He also taught me how to build a position in tranches instead of going all in, and pushed my research deeper than I'd have taken it on my own. Today I put those two lessons together and did something I've been building toward for weeks. I moved my whole book into a concentrated portfolio of my own picks. My research, my theses, my mistakes now. A handful of names I understand deeply, real cash on the side, and a small hedge underneath in case the whole thing cracks. I'm not going to pretend this isn't riskier. It is. A concentrated book can fall twice as hard as a diversified one, and I've done the math on exactly how much it can hurt in a bad year. I walked into this with my eyes open, not on a hype day, not chasing a dip, just a calm decision that it was time to take the wheel. Excited for what comes next. Genuinely excited to learn from it, including the parts that go wrong. Six months ago I followed. Now I'm driving. Same humility, more responsibility. NFA, just sharing the journey.

Stanley Druckenmiller once said: “Put all your eggs in one basket and watch the basket very carefully.” I think about this a lot because this is pretty much how I invest. The stock market is ultimately a game of probabilities. Nothing is guaranteed. You can spend hundreds of hours researching a company, know it inside out and still be wrong. But the whole point of doing that work is to improve your odds. With trading, I accept that I will be wrong plenty of times. I just want to be right more often than I'm wrong and make more from my winners than I lose from my losers. My main portfolio is different. I don't want to make 50 bets and hope 30 work. I want to find a handful of opportunities where I've done enough research that I'm comfortable putting a meaningful amount of money behind them. Of course concentration can destroy you if you're wrong. Druckenmiller himself has had huge losses throughout his career. But you also don't need many truly great investments in your lifetime. If you find one, understand what you own, put a meaningful amount of money into it and you're right, that one decision can change your entire portfolio. That's why the S&P 500 has never really suited me. There's nothing wrong with owning it, and for most people it probably makes sense. It's just not how I want to invest. If I believe I've found something exceptional, I don't want it buried among 499 other companies. I want it to matter.

A lot of people hear “peptides are not FDA approved” and immediately stop thinking. I think that’s the wrong way to look at it. FDA approval does not automatically mean something is healthy, risk-free or good for us. Cigarettes are legal. Alcohol is legal. Ultra-processed food is legal. There are plenty of things we consume every day that can damage our health. For me, the questions are much more important. What does the research say? What are the risks and benefits? What dose is being used? Where is it coming from? And is it being used properly? That’s how I look at peptides. I think one of the biggest misconceptions is that peptides are just some foreign chemical being injected into the body. Peptides are simply short chains of amino acids, and many already exist naturally in our bodies. They act like signals, telling different parts of the body what to do. Some affect appetite, some affect hormones, some affect inflammation and some are involved in healing and recovery. Of course, that doesn’t mean every peptide is safe. Insulin is natural, but the wrong dose can kill you. Growth hormone is natural, but abusing it can cause serious problems. Something being natural doesn’t automatically make it safe, just like something being FDA approved doesn’t automatically make it healthy. When I first started researching peptides, my first thought wasn’t “has the government approved this?” or “are big pharmaceutical companies selling it?” I wanted to know what the research actually says. What studies have been done? What are the side effects? What are people using them for? What has actually been proven and what is still early? I think that’s a much better way to look at this space. The problem is that peptides are a huge category and the evidence varies massively. Some peptide-based drugs, such as GLP-1s, have been studied extensively and are already widely used in medicine. Others look promising but are still very early, with limited data in humans. Then you have peptides that have become popular with athletes and biohackers despite there being nowhere near enough research to properly understand the risks or long-term effects. And this is where I think the real problem starts. The demand is already there. But when people can’t access these products through doctors and pharmacies, some of that demand moves towards “research only” websites, underground sellers and unregulated sources. You then have people injecting products where they may not even know exactly what is in the vial, how pure it is or whether the dose is accurate. That’s why I think regulation is important. This is just my opinion and not medical advice. I’m currently researching peptides for personal reasons and I’m also an investor in $HIMS.

Warren Buffett’s style of investing isn’t popular with everyone because it requires something most people don’t have, patience. Everyone wants to get rich quickly. Buffett’s approach is about getting rich slowly and letting compounding do the work. That’s much harder than it sounds.

Anthropic is preparing to IPO. Let’s forget the valuation for a second and look at how much they’re going to spend on compute. Anthropic has around $518B of future cloud, compute and infrastructure commitments over the coming years. Just look at what they’ve already secured: → Amazon: up to 5GW and $100B+ over 10 years → Google/Broadcom: 5GW of TPU capacity → Microsoft: $30B of Azure capacity and up to 1GW → AMD: up to 2GW of GPU capacity → SpaceX: 300MW+ and 220,000+ NVIDIA GPUs → Akamai: $11.6B over 7 years And this is just Anthropic. Now add OpenAI, xAI, Meta, Google and everyone else competing for the same power, GPUs and data center capacity. It may sound crazy given how much has already been spent, but I think we’re just getting started.